- Home
- RF vs MRNA Comparison
RF vs MRNA Comparison
Compare RF & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RF | MRNA |
|---|---|---|
| Founded | 1970 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 21.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RF | MRNA |
|---|---|---|
| Price | $28.41 | $44.53 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 12 |
| Target Price | $29.44 | ★ $34.27 |
| AVG Volume (30 Days) | ★ 9.0M | 4.9M |
| Earning Date | 04-17-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $14.98 | $9.36 |
| Revenue Next Year | $3.82 | $15.43 |
| P/E Ratio | $13.07 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $20.55 | $22.28 |
| 52 Week High | $31.53 | $59.55 |
Technical Indicators
Market Signals| Indicator | RF | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 33.69 |
| Support Level | $27.70 | $23.52 |
| Resistance Level | $29.12 | $55.36 |
| Average True Range (ATR) | 0.59 | 2.84 |
| MACD | 0.03 | -1.03 |
| Stochastic Oscillator | 75.26 | 6.46 |
Price Performance
Historical ComparisonAbout RF Regions Financial Corporation
Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of Sept. 30, 2025. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.